Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Ikena Oncology
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04200963CT.gov A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urinary Bladder Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ik-175 (this asset) | Ikena Oncology | P1 | CC · 47 |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Fred Hutchinson Cancer Center | P2 | BB |
| Atezolizumab | National Cancer Institute (NCI) | P2 | BB |
| Trastuzumab | Iambic Therapeutics, Inc | P2 | BB |
| Carboplatin | Iambic Therapeutics, Inc | P2 | BB |
| Pembrolizumab | Fred Hutchinson Cancer Center | P2 | BB |
| Nivolumab | M.D. Anderson Cancer Center | P2 | B |
| Adriamycin | M.D. Anderson Cancer Center | P2 | B |
| Cis-Diamminedichloroplatinum Ii | G1 Therapeutics, Inc. | P2 | B |
+37 more in the Urinary Bladder Cancer cohort
Other indications for ik-175
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Urothelial Neoplasm | — | P1 | CC · 47 |
| Urinary Bladder Disorder | — | P1 | CC · 47 |
| Bladder Transitional Cell Carcinoma | — | P1 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterBB
- AtezolizumabNational Cancer Institute (NCI)BB
- TrastuzumabIambic Therapeutics, IncBB
- CarboplatinIambic Therapeutics, IncBB
- PembrolizumabFred Hutchinson Cancer CenterBB
Citation
Floatz Terminal. ik-175 in Urinary Bladder Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ik-175-urinary-bladder-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →